Senescence-associated signature based on immunotherapy response sequencing reveals PPIL3 as target for bladder cancer treatment and prognosis prediction

BackgroundBladder cancer (Bca) remains a major genitourinary malignancy with unmet needs in immunotherapy optimization. Despite advancements in immune checkpoint inhibitors (ICIs), challenges persist, including low response rates and drug resistance. Emerging evidence links tumor cell senescence to...

Full description

Bibliographic Details

Published in:	Frontiers in Immunology
Main Authors:	Kaixuan Du, Ning Kang, Yuda Lin, Kaipeng Jia, Chong Shen, Zhouliang Wu, Hailong Hu
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2025-06-01
Subjects:	senescence immunotherapy bladder cancer PPIL3 therapeutic target
Online Access:	https://www.frontiersin.org/articles/10.3389/fimmu.2025.1613056/full